Characterization of genitourinary drug approvals by the FDA, 2020-2024.

Authors

David J. Benjamin (ORCID: https://orcid.org/0000-0002-2392-886X)
Arash Rezazadeh

Institutions

Hoag Memorial Hospital Presbyterian (US)
University of California, Irvine (US)

Publication Details

Journal: Journal of Clinical Oncology
Published: 2025-02-10
DOI: https://doi.org/10.1200/jco.2025.43.5_suppl.872
Citations: 1
Primary Topic: Reproductive Health and Technologies
Type: article
Field-Weighted Citation Impact: 1.70

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Characterization of genitourinary drug approvals by the FDA, 2020-2024.

David J. Benjamin, Arash Rezazadeh

Feb 10, 2025

1 citations

Journal of Clinical Oncology

Reproductive Health and Technologies

1.70

article

Characterization of genitourinary drug approvals by the FDA, 2020-2024.

David J. Benjamin, Arash Rezazadeh

February 10, 2025article en

1 citations

Abstract

No abstract available for this paper.

Journal of Clinical OncologyVol. 43(5_suppl)

Hoag Memorial Hospital Presbyterian (US), University of California, Irvine (US)

Openalex Percentile: Top 20%

Reproductive Health and Technologies

1.70

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Characterization of genitourinary drug approvals by the FDA, 2020-2024. — David J. Benjamin, Arash Rezazadeh · Journal of Clinical Oncology (2025) | TGRS Research Map | TGRS